期刊
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
卷 159, 期 -, 页码 -出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2021.103241
关键词
UTUC; Upper tract urothelial cancer; Immune checkpoint inhibitors; Immunogenicity; Renal pelvis; Urothelial cancer
The systematic review and meta-analysis of clinical studies on advanced UTUC patients treated with ICI did not show statistically significant effects in reducing the risk of death compared to standard chemotherapy. Subgroup analyses from randomized clinical trials are needed to provide more conclusive evidence.
Background: Advanced upper tract urothelial carcinoma (UTUC) has different molecular and genetic features from the commonest carcinoma of the bladder, suggesting a possible different sensitivity to immune-checkpoint inhibitors (ICI). Methods: A systematic review and meta-analysis of all relevant clinical studies including advanced UTUC patients treated with ICI was conducted according to PRISMA guidelines. Results: Six prospective trials for a total 2537 patients, including 396 (15.6 %) with advanced UTUC, were eligible for the analysis. In UTUC patients, the pooled ORR was 21.2 % (95 % CI, 12.5 %-33.7 %); the risk of death was reduced by 24 % over the standard platinum-based chemotherapy, but this was not statistically significant (hazard ratio = 0.76; 95 % confidence interval, 0.41-1.40; p = 0.37, chi 2 = 3.28, p = 0.07; I2 = 70 %). Conclusions: The current evidence does not support a statistically significant effect from ICI over the standard treatment for advanced UTUC patients. Properly performed pre-planned subgroup analyses from randomized clinical trials are eagerly awaited.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据